<DOC>
	<DOCNO>NCT01982097</DOCNO>
	<brief_summary>This local , prospective , multicenter , non-interventional study document observational data patient routine treatment metastatic RCC Nexavar cytoreductive nephrectomy . It 's plan well understand impact cytoreductive nephrectomy Nexavar efficacy possibly define patient get benefit Nexavar cytoreductive nephrectomy .</brief_summary>
	<brief_title>Sorafenib Neoadjuvant Therapy Before Cytoreductive Nephrectomy Patients With Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Male female patient â‰¥ 18 year old Patients untreated metastatic RCC decision neoadjuvant treatment Nexavar cytoreductive nephrectomy case clinical feasibility resumption treatment Nexavar nephrectomy make time study enrollment Life expectancy least 16 week Patients sign informed consent form Diagnosis second malignancy within last 5 year , except adequately treat basal cell carcinoma , squamous cell skin cancer , situ cervical cancer . All contraindication accord Russian marketing authorization : Hypersensitivity sorafenib excipients . Pregnancy breastfeed . Age le 18 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Non-interventional</keyword>
	<keyword>Nexavar</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Carcinoma , renal cell</keyword>
	<keyword>Neoadjuvant</keyword>
	<keyword>Nephrectomy</keyword>
	<keyword>Russian Federation</keyword>
</DOC>